Form 4: ADC Therapeutics Director Acquires and Sells Shares

Victor Sandor, a Director at ADC Therapeutics SA, reported transactions involving the acquisition of 45,000 restricted stock units and the subsequent sale of 12,600 common shares.

Summary

• Victor Sandor, a Director at ADC Therapeutics SA, acquired 45,000 restricted stock units (RSUs) on June 1, 2026, as an annual grant under the company's 2019 Equity Incentive Plan.
• These RSUs vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Shareholders, contingent on continued service.
• On June 3, 2026, Sandor disposed of 12,600 common shares, with 12,600 shares withheld by the issuer to cover tax obligations related to the vesting of previously granted RSUs, at a price of $3.08 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to compensation and tax obligations, rather than significant strategic or financial performance indicators.

Positives

• Director Victor Sandor received an annual grant of 45,000 RSUs, indicating continued equity incentive for service.
• The RSUs are structured to vest over time, aligning with continued service and potentially long-term commitment.

Negatives

• 12,600 common shares were disposed of, with a portion withheld for tax obligations, reducing the director's direct shareholding.

Future Outlook

The RSUs granted to Victor Sandor are subject to vesting conditions tied to continued service and the 2027 Annual Meeting of Shareholders, indicating a forward-looking incentive structure.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported on Form 4, are routine for directors and officers as part of compensation and equity incentive plans. The acquisition of RSUs and subsequent withholding for taxes are standard practices in the biotechnology and pharmaceutical sectors where equity-based compensation is common.

Stakeholder Impact

• Shareholders: The transactions are routine and do not indicate a significant change in the director's beneficial ownership or company strategy.

Next Steps

• Vesting of RSUs on the earlier of one year from the grant date or the 2027 Annual Meeting of Shareholders, subject to continued service.

Key Dates

Keywords

ADC Therapeutics SA, ADCT, Form 4, Insider Trading, Restricted Stock Units, Equity Incentive Plan, Director Compensation, Shareholder Meeting